Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.63M | $-201.14M | $-1.35 |
| 2024 | $2.98M | $-195.88M | $-1.65 |
| 2023 | $0.00 | $-198.13M | $-2.18 |
| 2022 | $0.00 | $-121.82M | $-1.46 |
| 2021 | $0.00 | $-165.37M | $-1.92 |
Social Signal Score
Earnings
Fri, Nov 6(in 3 months)
Consensus estimate $-0.23 per share
Typical surprise -13.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.24 vs $-0.26beat
- Thu, May 7$-0.28 vs $-0.24miss
- Tue, Mar 3$-0.22 vs $-0.25beat
- Fri, Nov 7$-0.32 vs $-0.28miss
- Thu, Aug 7$-0.41 vs $-0.36miss
- Thu, May 8$-0.40 vs $-0.32miss
Estimates and results for PRME via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
PRMEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsseekingalpha.com·6h ago·Positive
Prime Medicine: Soon In The Clinic Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and immunology/oncology, with leading preclinical efficacy and multi-billion-dollar addressable markets. Recent IND/CTA clearances, RMAT designation, and patent wins highlight PRME's clinical and strategic momentum despite a 54% stock decline from 52-week highs.
View source ↗